Skip to main content
. 2017 Oct 13;6(12):2787–2795. doi: 10.1002/cam4.1228

Figure 4.

Figure 4

Effects of Sorafenib on tumor growth were significantly correlated with basal pERK levels in patient‐derived primary HCC xenograft model. (A and B) The effects of Sorafenib in patient‐derived primary HCC xenograft models with different expression of pERK were evaluated. (C) The volume of patient‐derived primary HCC xenograft models treated with 30 mg/kg Sorafenib or DMSO (mean±SEM; *P<0.05).